Population pharmacokinetics of piperacillin/tazobactam in critically ill young children

Pediatric Infectious Disease Journal

Volumn 33, Issue 2, 2014, Pages 168-173

  Cies, Jeffrey J ^a,b,c   Shankar, Venkat ^d   Schlichting, Christine ^a,b   Kuti, Joseph L ^e  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e HARTFORD HOSPITAL   (United States)

Author keywords

critically ill children; pharmacokinetics; piperacillin; tazobactam

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ACCURACY; ANTIBIOTIC SENSITIVITY; BIOASSAY; BLOOD SAMPLING; BODY WEIGHT; CHILD; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GROUPS BY AGE; HUMAN; INFANT; INTENSIVE CARE UNIT; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW;

BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CRITICAL ILLNESS; FEMALE; HUMANS; INFANT; INTENSIVE CARE UNITS, PEDIATRIC; MALE; MONTE CARLO METHOD; PENICILLANIC ACID; PHILADELPHIA; PIPERACILLIN;

EID: 84892975681     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182a743c7     Document Type: Review

References (39)

1. Roberts JA, Roberts MS, Robertson TA, et al. Piperacillin penetration into tissue of critically ill patients with sepsis - Bolus versus continuous administration Crit Care Med. 2009;37926-933
2. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time. Crit Care Med. 1998;262078-2086
3. Garnacho-Montero J, Garnacho-Montero C, Cayuela A, et al. Timing of adequate antibiotic therapy is more determinant of outcome than TNF and IL-10 polymorphisms in septic patients. Crit Care. 2006;10R111
4. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003;312742-2751
5. Cunha BA. Antibiotic treatment of sepsis. Med Clin North Am. 1995;79 551-558
6. Harbarth S, Garbino J, Pugin J, et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003;115529-535
7. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections a risk factor for hospital mortality among critically ill patients. Chest. 1999;115462-474
8. MacArthur RD, Miller M, Albertson T, et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis experience from the MONARCS trial. Clin Infect Dis. 2004;38284-288
9. Rice TW, Bernard GR. Therapeutic intervention and targets for sepsis. Annu Rev Med. 2005;56225-248
10. Roberts JA, Lipman J Antibiotic dosing in intensive care Pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Cin Pharmacokinet. 2006;45755-773
11. Courter JD, Kuti JL, Girotto JE, et al. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer. 2009;53379-385
12. Reed MD, Goldfarb J, Yamashita TS, et al. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother. 1994;382817-2826
13. Piperacillintazobactam (Zosyn®) [package insert]. Philadelphia, PA Pfizer Pharmaceuticals; 2012
14. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33278-285
15. Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in men a cross-sectional and longitudinal study. J Gerontol. 1976;31 155-163
16. Chien S, Wells TG, Blumer JL, et al. Levofloxacin pharmacokinetics in children. J Clin Pharmacol. 2005;45153-160
17. Bartelink IH, Rademaker CM, Schobben AF, et al. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet. 2006;451077-1097
18. Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of betalactams may account for therapeutic failure in patients with septic shock. Crit Care Med. 2001;29385-391
19. Drusano GL. Antimicrobial pharmacodynamics critical interactions of'bug and drug'. Nat Rev Microbiol. 2004;2289-300
20. Drusano GL. Prevention of resistance Agoal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;3642-50
21. Tam VH, Louie A, Lomaestro BM, et al. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy. 2003;23291-295
22. Leary RJ, Schumitzky A, Van Guilder M. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PKPD) models. In Proceedings, Fourteenth IEEE Symposium on Computer-based Medical Systems. Bethesda IE Computer Society; 2001389-394
23. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978;6165-175
24. DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy. 2007;27333-342
25. Centers for Disease Control and PreventionWorld Health Organization Child Growth Standards. Available at httpwww.cdc.govgrowthcharts who charts.htm. Accessed August 14, 2012
26. Lexi-Comp Online. Hudson, Ohio Lexi-Comp, Inc.; 2012
27. Pediatric & Neonatal Lexi-Drugs Online. Hudson, Ohio Lexi-Comp, Inc.; 2012
28. Thomson Micromedex Web site. Available at httpuspdi.micromedex. com. Accessed December 15, 2012
29. Barone MA, ed. The Harriet Lane handbook A Manual for Pediatric House Officers. 16th ed. St. Louis Mosby-Year Book; 2002
30. Li Z, Chen Y, Li Q, et al. Population pharmacokinetics of piperacillin tazobactam in neonates and young infants. Eur J Clin Pharmacol. 2013;691223-1233
31. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;491-16
32. Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic initial β-lactam concentrations in select critically ill patients association between augmented renal clearance and low trough drug concentrations. Chest. 2012;14230-39
33. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37840-851; quiz 859
34. Auclair B, Ducharme MP. Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses. Antimicrob Agents Chemother. 1999;431465-1468
35. Muszynski JA, Knatz NL, Sargel CL, et al. Timing of correct parenteral antibiotic initiation and outcomes from severe bacterial community-acquired pneumonia in children. Pediatr Infect Dis J. 2011;30295-301
36. Li C, Kuti JL, Nightingale CH, et al. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol. 2006;461171-1178
37. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection clinical implications of an extendedinfusion dosing strategy. Clin Infect Dis. 2007;44357-363
38. Tamma PD, Turnbull AE, Milstone AM, et al. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia Clin Infect Dis. 2012;55799-806
39. Clinical and Laboratory Standards Institute. Summary minutes Subcommittee on Antimicrobial Susceptibility Testing. Available at http www.clsi. orgContentNavigationMenuCommitteesMicrobiologyAST ArchiveofPreviousEventsASTJanuary2011.pdf. Accessed September19, 2012